Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.
about
Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophySildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencyNitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities (review)Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathyCurrent understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophyProteomic analysis reveals new cardiac-specific dystrophin-associated proteinsDystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype.Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies.Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout miceArginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy.Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.Neuronal nitric oxide synthase-rescue of dystrophin/utrophin double knockout mice does not require nNOS localization to the cell membraneDelayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic glutathione resource.A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophyCyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Autocrine VEGF signaling is required for vascular homeostasis.Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart.Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophyNitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters.Whole body periodic acceleration is an effective therapy to ameliorate muscular dystrophy in mdx mice.AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs.The Effects of Experimental Sleep Apnea on Cardiac and Respiratory Functions in 6 and 18 Month Old Dystrophic (mdx) Mice.Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Dystrophin-glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signalingDilated cardiomyopathy: a tale of cytoskeletal proteins and beyond.Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy.Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach.Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy.Vascular-targeted therapies for Duchenne muscular dystrophyMajor basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy.C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout miceLoss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.
P2860
Q24295360-3F506C96-398E-4F9F-81A7-E7F42BA09B42Q24655371-6C0F05DA-6F22-4483-BEF1-4AFA013D4E55Q26823520-78DC1FB7-FCF8-4518-A07E-04B8BC9C0BA4Q27006945-A1FC1609-C969-43E7-970B-052F2B4D2450Q28082625-346733EE-8D75-4A60-9746-3485A173DA28Q28482614-97BA02C4-8B8A-4FAB-8544-2558B7D1B819Q30493760-164EF262-BBDD-4F7F-8E5E-C870114CEE29Q33265240-87F8AE89-3E3C-4E5D-8490-6E3C301FD6A1Q33375717-60AE9C62-87D4-4A32-B175-77DAE30F546CQ33588636-B28A2E4E-242B-4789-94F6-0538732149A8Q33649295-26F78463-F6E7-4B13-BFD4-406DAAB5953DQ33871052-F43F090B-34AD-4F6C-ADC3-4DC79CEA9305Q33925312-0A6D3B5B-0B5B-4C70-A587-3D82D38C1CCCQ34049251-D272E7A2-CD4C-40A0-8793-0965B4CF1B7CQ34086953-9102F63E-69DC-465E-858F-21F1807D82C9Q34175938-5C369AA4-8F41-47FC-8CA6-2885E76D79D8Q34277031-4FFE36CC-8072-4129-B5B1-F8BC12F00566Q34279254-B5DD1F32-2CF3-4062-AD13-00D189EDEA93Q34315276-CABAE65F-EDD4-4AF9-A808-56B4969384B6Q34443661-92D606AE-09C9-4D0F-B5F0-98696D2B9B3AQ34508301-57169CC1-4E88-4129-9D4C-7591B8CFD48CQ34582749-8F6EA987-14F9-459F-8CF3-D0B6469FCCE5Q35175749-D4945565-1085-4EBD-9D5A-2BB0A3CB42C6Q35195095-9DCE4030-3CA5-4B6C-8DEC-B974FD6E0B89Q35236912-03510CA8-98A0-4572-A408-A4858CF1A486Q35285784-1B0D7621-00C4-49FA-8D08-EEA0621F172FQ35819142-A51B82B9-E5D1-4ADE-908F-4B2C946EC1D1Q35903669-2A0E348E-B037-4D3B-B997-E589B697EA56Q35928246-377C8195-7810-4A67-94F4-D8D60304F240Q35986842-9DD8A750-9E89-4522-A6D5-241161A18869Q36268410-77D58EE6-DD25-4C08-898C-8BB1F582BAE8Q36501691-A48847BF-3215-4753-AFDB-EE6BE9CFE9D9Q36599311-639E99F6-2B73-483E-9689-40E564EEFAF9Q36691646-C8AA6572-F02F-4347-9FD0-3F944EF89358Q36707428-ED4A2C12-4380-456C-A9AD-A4D897DDB52AQ36835180-262D27EB-1591-4DDB-9932-89FB472C0DE8Q36952488-366581B5-A944-416B-9593-5F1DFDBD83D9Q36968836-895ECCC4-C6C9-4A93-B16B-4649CE09CF97Q37312499-8B532C5A-9814-4E8C-B215-0AEC0AB74773Q37420916-089F2708-7D0A-4F72-BEED-623C1720D8E7
P2860
Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@en
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@nl
type
label
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@en
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@nl
prefLabel
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@en
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@nl
P2093
P356
P1476
Cardiomyopathy in dystrophin-d ...... e transgene in the myocardium.
@en
P2093
James G Tidball
Kenneth P Roos
Maria C Jordan
Michelle Wehling-Henricks
P304
P356
10.1093/HMG/DDI197
P577
2005-05-25T00:00:00Z